

Henry Ford Health

## Henry Ford Health Scholarly Commons

---

Urology Articles

Urology

---

5-1-2022

### Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease

Spencer C. Hiller

Stephanie Daignault-Newton

Ivan Rakic

Susan Linsell

Bronson Conrado

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/urology\\_articles](https://scholarlycommons.henryford.com/urology_articles)

---

#### Recommended Citation

Hiller SC, Daignault-Newton S, Rakic I, Linsell S, Conrado B, Jafri SM, Rubenstein R, Abdelhady M, Fischer CP, Gimenez E, Sarle R, Roberts WW, Maitland C, Yousif R, Elgin R, Galejs L, Konheim J, Leavitt D, Stockall E, Fontera JR, Wolf JS, Hollingsworth JM, Dauw CA, and Ghani KR. Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease. *Urol Pract* 2022; 9(3):253-263.

This Article is brought to you for free and open access by the Urology at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Urology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

---

## Authors

Spencer C. Hiller, Stephanie Daignault-Newton, Ivan Rakic, Susan Linsell, Bronson Conrado, S. M. Jafri, Ronald Rubenstein, Mazen Abdelhady, C. Peter Fischer, Elena Gimenez, Richard Sarle, William W. Roberts, Conrad Maitland, Rafid Yousif, Robert Elgin, Laris Galejs, Jeremy Konheim, David Leavitt, Eric Stockall, J. Rene Fontera, J. Stuart Wolf Jr., John M. Hollingsworth, Casey A. Dauw, and Khurshid R. Ghani

UPJ Insight

Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease

Spencer C. Hiller <sup>ID</sup>, Stephanie Daignault-Newton, Ivan Rakic et al.


Correspondence: Spencer C. Hiller (email: [spehill@med.umich.edu](mailto:spehill@med.umich.edu))

Full-length article available at [auajournals.org/10.1097/UPJ.0000000000000302](https://auajournals.org/10.1097/UPJ.0000000000000302).

**Study Need and Importance:** Ureteral stent placement following uncomplicated ureteroscopy for urinary stone disease occurs in over two-thirds of cases and is associated with pain, urinary symptoms and increased risk of emergency department visits. Routine stenting occurs despite American Urological Association guidelines that recommend stents be omitted following uncomplicated ureteroscopy. Underutilization of ureteral stent omission may be an indication of uncertainty regarding scenarios suitable for stent vs no stent. In this study, we defined the scenarios appropriate for ureteral stent omission by use of RAM (RAND/UCLA Appropriateness Method).

**What We Found:** We convened a panel of 15 urologists from the Michigan Urological Surgery Improvement Collaborative (MUSIC), representing diverse practices across the State of Michigan, to implement RAM. We created a consensus definition of uncomplicated ureteroscopy and scored clinical scenarios for appropriateness criteria for stent omission (1–3: inappropriate; 4–6: uncertain; 7–9: appropriate). The majority of scenarios appropriate for stent omission were pre-stented (81%). Findings were matched to ureteroscopy cases within the MUSIC registry. Stents were placed in 61% of cases meeting appropriateness criteria for stent omission.

**Limitations:** It was not possible to capture every variable under consideration during stent omission decision making, and several factors were not included because they could not be objectively quantified. Our panel and retrospective analysis included only practices in Michigan, so



**Figure.** MUSIC physician guidance on appropriateness for stent omission following uncomplicated ureteroscopy. UA, urinalysis. URS, ureteroscopy.

our results may not translate to other national or global trends in practice.

**Interpretation for Patient Care:** We comprehensively defined uncomplicated ureteroscopy as well as those situations appropriate and inappropriate for stent omission. Stent omission following uncomplicated ureteroscopy is currently underutilized in practice, and there is substantial variation. We have now implemented stent omission criteria in Michigan with the goal to reduce the overuse of stenting after uncomplicated ureteroscopy (see figure).

# Appropriateness Criteria for Ureteral Stent Omission following Ureteroscopy for Urinary Stone Disease

Spencer C. Hiller<sup>1\*</sup>,<sup>ID</sup> Stephanie Daignault-Newton,<sup>1</sup> Ivan Rakic,<sup>2</sup> Susan Linsell,<sup>1</sup> Bronson Conrado,<sup>1</sup> S. Mohammad Jafri,<sup>3</sup> Ronald Rubenstein,<sup>3</sup> Mazen Abdelhady,<sup>4</sup> C. Peter Fischer,<sup>5</sup> Elena Gimenez,<sup>6</sup> Richard Sarle,<sup>7</sup> William W. Roberts,<sup>1</sup> Conrad Maitland,<sup>8</sup> Rafid Yousif,<sup>9</sup> Robert Elgin,<sup>10</sup> Laris Galejs,<sup>11</sup> Jeremy Konheim,<sup>6</sup> David Leavitt,<sup>12</sup> Eric Stockall,<sup>13</sup> J. Rene Fontera,<sup>14</sup> J. Stuart Wolf, Jr.,<sup>15</sup> John M. Hollingsworth,<sup>1</sup> Casey A. Dauw<sup>1</sup> and Khurshid R. Ghani<sup>1</sup> for the Michigan Urological Surgery Improvement Collaborative

<sup>1</sup>Department of Urology, University of Michigan, Ann Arbor, Michigan

<sup>2</sup>Wayne State University School of Medicine, Detroit, Michigan

<sup>3</sup>Department of Urology, William Beaumont Hospital, Royal Oak, Michigan

<sup>4</sup>Department of Urology, Detroit Medical Center, Detroit, Michigan

<sup>5</sup>Associates in Urology, Chelsea, Michigan

<sup>6</sup>IHA-Urology, Ypsilanti, Michigan

<sup>7</sup>Sparrow Medical Group, Lansing, Michigan

<sup>8</sup>Sherwood Medical Center, Detroit, Michigan

<sup>9</sup>Lansing Institute of Urology, Lansing, Michigan

<sup>10</sup>Michigan Institute of Urology, St. Claire Shores, Michigan

<sup>11</sup>Michigan Institute of Urology, Howell, Michigan

<sup>12</sup>Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan

<sup>13</sup>Capital Urological Associates, Okemos, Michigan

<sup>14</sup>Michigan Institute of Urology, Troy, Michigan

<sup>15</sup>Dell Medical School, University of Texas, Austin, Texas

## Abstract

**Introduction:** To bridge the gap between evidence and clinical judgment, we defined scenarios appropriate for ureteral stent omission after uncomplicated ureteroscopy (URS) using the RAND/UCLA Appropriateness Method. We retrospectively assessed rates of appropriate stent omission, with the goal to implement these criteria in clinical practice.

**Methods:** A panel of 15 urologists from the MUSIC (Michigan Urological Surgery Improvement Collaborative) met to define uncomplicated URS and the variables that influence stent omission decision making. Over 2 rounds, they scored clinical scenarios for appropriateness criteria (AC) for stent omission based on a combination of variables. AC were defined by median scores of 1 to 3 (inappropriate), 4 to 6 (uncertain) and 7 to 9 (appropriate). Multivariable analysis determined the

## Abbreviations and Acronyms

AC = appropriateness criteria

AUA = American Urological Association

EAU = European Association of Urology

MUSIC = Michigan Urological Surgery Improvement Collaborative

RAM = RAND/UCLA Appropriateness Method

UAS = ureteral access sheath

URS = ureteroscopy

Support: The Michigan Urological Surgery Improvement Collaborative (MUSIC) is funded by Blue Cross and Blue Shield of Michigan (BCBSM) as part of the BCBSM Value Partnerships program. CPF is supported by the National Institutes of Health. RE is supported by the National Institutes of Health, Howard Hughes Medical Institute and the Wellcome Trust. JMH has grant support from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK12170901).

Conflict of Interest: RS: Myovant Speakers Bureau, Genomic Health (past); RE: Johnson and Johnson; DL: Boston Scientific Corporation, Richard Wolf Medical; JSW: Ambu Corporation, Applaud Medical, Calyxo, *Urology Times*;

CAD: Boston Scientific, AURIS Robotics; KRG: Boston Scientific, Coloplast, Storz, Olympus, Lumenis.

Ethics Statement: Each MUSIC practice obtained an approval (Henry Ford IRB #8045, Wayne State University IRB #032112MR2E) or an exemption by the local Institutional Review Board for participation in the Collaborative.

\* Correspondence: Department of Urology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, Michigan 48109 (telephone: 734-936-7030; FAX: 734-232-2400; email address: spehill@med.umich.edu).

association of each variable with AC scores. Uncomplicated URS cases in the MUSIC registry were assigned AC scores and stenting rates assessed.

**Results:** Seven variables affecting stent decision making were identified. Of the 144 scenarios, 26 (18%) were appropriate, 88 (61%) inappropriate and 30 (21%) uncertain for stent omission. Most scenarios appropriate for omission were pre-stented (81%). Scenarios with ureteral access sheath or stones >10 mm were only appropriate if pre-stented. Stenting rates of 5,181 URS cases correlated with AC scores. Stents were placed in 61% of cases appropriate for omission (practice range, 25% to 98%).

**Conclusions:** We defined objective variables and AC for stent omission following uncomplicated URS. AC scores correlated with stenting rates but there was substantial practice variation. Our findings demonstrate that the appropriate use of stent omission is underutilized.

**Keywords:** ureteroscopy, stents, quality improvement, urinary calculi

Guidelines from the European Association of Urology (EAU) and American Urological Association (AUA) state ureteral stents may be omitted following uncomplicated ureteroscopy (URS) in some situations.<sup>1,2</sup> However, stenting remains a common practice, occurring in over two-thirds URS for urinary stone disease.<sup>3,4</sup> Stents are associated with pain and urinary symptoms,<sup>5</sup> as well as increased risk of an emergency department visit after URS.<sup>4,6,7</sup> These unplanned encounters substantially increase the cost of URS.<sup>8</sup> Importantly, overuse of stenting can lead to unnecessary patient suffering and loss of income due to work incapacity.<sup>9</sup> Therefore, efforts to decrease stenting rates may improve health-related quality of life and reduce health care costs.

Idiosyncratic physician practice patterns are recognized as one of the strongest determinants of treatment variation.<sup>10</sup> In a recent publication, significant surgeon variation in stenting after URS was observed, ranging from 10% to 100%.<sup>4</sup> This variation may be an indication of uncertainty regarding the criteria outlined by the AUA and EAU guidelines. Specifically, the definition of uncomplicated URS or which scenarios are most suitable for stent omission.<sup>1,2</sup> One intervention that addresses variation and bridges the gap between evidence and clinical judgment is the RAND/UCLA Appropriateness Method (RAM) and creation of appropriateness criteria (AC).<sup>11,12</sup> This method has been used to reduce the inappropriate use of procedures, including percutaneous coronary interventions.<sup>12,13</sup> In urology, the RAM has been used to develop AC for active surveillance of prostate cancer.<sup>14</sup> Dissemination of AC helped decrease surgery for low-risk prostate cancer in the Michigan Urological Surgery Improvement Collaborative (MUSIC).<sup>15,16</sup>

In this context, we undertook a quality improvement project following the RAM with a diverse panel of urologists in MUSIC to 1) review the evidence supporting stent omission following URS for urinary stone disease and define uncomplicated URS, 2) develop a list of variables that determine eligibility for stent omission, 3) assign AC scores for all combinations of these variables and 4) retrospectively

measure stenting rates within the MUSIC registry for each AC score. Our long-term goals are to reduce uncertainty regarding stent omission decision making, increase appropriate use of stent omission, improve patient outcomes and reduce avoidable health care utilization.

## Materials and Methods

### MUSIC

MUSIC was established in 2011, in partnership with Blue Cross Blue Shield of Michigan, and is a statewide quality improvement collaborative consisting of over 90% of urologists in the State of Michigan. Details on the ROCKS (Reducing Operative Complications from Kidney Stones) initiative and clinical registry have been previously described.<sup>4,17,18</sup> Each MUSIC practice has obtained an exemption or approval by the local Institutional Review Board for participation in the collaborative. This study was conducted by the MUSIC coordinating center and, thus, participants were limited to those within the state of Michigan.

### RAM

RAM is a multistep process that requires a panel of experts in the field to score and, unlike the traditional Delphi method, discuss clinical scenarios for appropriateness a chosen intervention.<sup>11</sup> We began the process by inviting all MUSIC urologists to participate in the panel. In accordance with the RAM manual, we included only urologists on our panel because no other specialty is involved in the decision-making process for stent omission.<sup>11</sup> We ultimately selected 15 urologists from 25 respondents in order to include a diverse group of panelists from a variety of practice types and sizes across Michigan (supplementary fig. 1, <https://www.urologypracticejournal.com>). Since our findings were to be implemented in Michigan, we did not include outside urologists. At the first meeting (round 1), panelists were provided a synthesis of the available evidence, including a

Uncomplicated Ureteroscopy
Age $\geq 18$ years
American Society of Anesthesiologists (ASA) score $< 3$
Not immunocompromised or pregnant
No evidence of functional/anatomic solitary kidney
No anatomic abnormalities (i.e. stricture, ureteropelvic junction obstruction, horse shoe kidney)
No urinary tract reconstruction
No uncorrected bleeding diathesis, anticoagulant and/or antiplatelet therapy
No history of neurogenic bladder or incomplete bladder emptying
No signs or symptoms of sepsis
No history of sepsis associated with urinary tract infection
No untreated positive urine culture
No stones in multiple locations (i.e. both ureter and kidney)
Stone size $\leq 15$ mm
Operative time $\leq 60$ minutes
No balloon dilation of the ureter
Unilateral procedure
No plan for second look procedure
Retrograde ureteroscopy only
No ureteral perforation or trauma

**Figure 1.** MUSIC AC panel consensus definition of uncomplicated URS.

literature review conducted by the MUSIC coordinating center (supplementary fig. 2, <https://www.urologypracticejournal.com>). Guideline statements from the AUA, EAU and UK National Institute for Health and Care Excellence were discussed by an expert in the field (JSW; supplementary fig. 3, <https://www.urologypracticejournal.com>).<sup>1,2,19</sup> At this meeting the panelists reached consensus on the definition of uncomplicated URS, for which ureteral stent omission was being considered (fig. 1). Following this, the panel had to decide on patient and surgical variables that determined stent omission decision making. At the conclusion of the meeting, consensus was reached on 7 variables: stone size ( $\leq 5$ ,  $>5$ – $\leq 10$  or  $>10$ – $\leq 15$  mm), stone location (kidney or ureter), pre-stent (yes or no), urinalysis or urine culture result (treated positive culture or negative), nonballoon ureteral dilation performed


(yes or no), ureteral access sheath (UAS) use (yes or no) and presence of “basketable”-sized residual stone fragments (yes or no; fig. 2). Based on all combinations of variables, this resulted in 192 clinical scenarios to be scored for stent omission appropriateness (supplementary fig. 4, <https://www.urologypracticejournal.com>).

The panelists then individually scored these scenarios for stent omission using AC scoring of 1 (highly inappropriate) to 9 (highly appropriate) over a 3-month period. Scores were collated by the MUSIC coordinating center and presented to panelists at a second-round meeting, where they reviewed the distribution of all the panelists scores for each scenario (supplementary fig. 5, <https://www.urologypracticejournal.com>). Panelists were given the opportunity to discuss each scenario and to change the variables. At this meeting, there was unanimous consensus to remove the “ureteral dilation” variable from scenarios with pre-stenting, decreasing the total scenarios to 144. The panel decided any pre-stented scenario that still required ureteral dilation during URS should not be considered uncomplicated. A MUSIC patient advocate was present and contributed to the discussion. At the conclusion of the meeting, panelists again individually scored each clinical scenario. We created a color-coded heatmap based on the median round 2 scores for appropriateness of stent omission. We also categorized scenarios on agreement, determined by the quintile of standard deviation of the round 2 scores for a given scenario. Any scenario with  $\geq 5$  panelists assigning an AC score between 1 to 3 and 7 to 9 were reclassified as uncertain, regardless of the actual median, per the RAM manual definition of disagreement.<sup>11</sup>

Variable	Categories	Definition
Stone size	$\leq 5$ mm	Maximum diameter of the single largest treated stone in millimeters
	$>5$ mm - $\leq 10$ mm	
	$>10$ mm - $\leq 15$ mm	
Stone location	Kidney	Treated stone or stones all located within the kidney - all calyces, renal pelvis and ureteropelvic junction
	Ureter	Treated stone or stones all located within the ureter - upper, mid, distal and ureterovesical junction
Pre-stent	Yes	Presence of a stent prior to therapeutic ureteroscopy
	No	Absence of a stent prior to therapeutic ureteroscopy
UA/Urine culture result	Treated positive culture	A positive preoperative urine culture that has been treated with an appropriate course of antibiotics
	Negative	Negative preoperative UA or urine culture
Ureteral dilation	Yes	Non-balloon mechanical ureteral dilation $>10$ French
	No	No dilation performed or use of a non-balloon ureteral dilator $\leq 10$ French performed
Ureteral access sheath	Yes	Ureteral access sheath of any size placed during ureteroscopy
	No	No ureteral access sheath used
Fragments	Yes	Fragments of a size that could be easily basketed left within the upper urinary tract at the conclusion of ureteroscopy
	No	Complete absence of fragments or presence of very small fragments (too small to be easily basketed) left within the upper urinary tract at the conclusion of ureteroscopy

**Figure 2.** Panel consensus definitions of the 7 variables that determine appropriateness for ureteral stent omission following uncomplicated URS. UA, urinalysis.

			Pre Stented					
			Negative Culture					
			Size ≤5mm		Size >5mm - ≤10mm		Size >10mm - ≤15mm	
			Ureter	Kidney	Ureter	Kidney	Ureter	Kidney
No Dilation	UAS -	Frag -	9	9	9	9	7	7
	UAS +	Frag -	8	8	8	7	6	6
	UAS -	Frag +	7	7	7	6	5	4
	UAS +	Frag +	7	7	6	5	3	4
			Not Pre Stented					
			Negative Culture					
			Size ≤5mm		Size >5mm - ≤10mm		Size >10mm - ≤15mm	
			Ureter	Kidney	Ureter	Kidney	Ureter	Kidney
No Dilation	UAS -	Frag -	9	9	7	7	5	4
	UAS +	Frag -	3	3	3	2	2	2
	UAS -	Frag +	6	5	3	2	2	1
	UAS +	Frag +	3	2	2	2	1	1
Dilation	UAS -	Frag -	4	4	3	3	2	1
	UAS +	Frag -	3	2	2	2	1	1
	UAS -	Frag +	3	2	2	2	1	1
	UAS +	Frag +	2	1	1	1	1	1
			Pre Stented					
			Treated Positive Culture					
			Size ≤5mm		Size >5mm - ≤10mm		Size >10mm - ≤15mm	
			Ureter	Kidney	Ureter	Kidney	Ureter	Kidney
No Dilation	UAS -	Frag -	8	8	8	8	7	7
	UAS +	Frag -	7	7	7	7	5	5
	UAS -	Frag +	6	5	4	5	2	2
	UAS +	Frag +	5	5	2	2	2	2
			Not Pre Stented					
			Treated Positive Culture					
			Size ≤5mm		Size >5mm - ≤10mm		Size >10mm - ≤15mm	
			Ureter	Kidney	Ureter	Kidney	Ureter	Kidney
No Dilation	UAS -	Frag -	7	5	4	4	3	2
	UAS +	Frag -	3	3	2	2	1	1
	UAS -	Frag +	3	3	2	2	1	1
	UAS +	Frag +	2	2	1	1	1	1
Dilation	UAS -	Frag -	5	3	2	2	1	1
	UAS +	Frag -	2	2	1	1	1	1
	UAS -	Frag +	2	1	1	1	1	1
	UAS +	Frag +	1	1	1	1	1	1



**Figure 3.** Heatmap of AC for ureteral stent omission after URS: 1—highly inappropriate, to 9—highly appropriate. Displayed are median scores for all 144 clinical scenarios. UAS+, UAS used. UAS-, no UAS used. Frag+, yes, fragments left behind. Frag-, no fragments left behind.

*Statistical Methods*


To assess the strength of the association of the panel variables with AC score, a logistic regression model was used with stent omission AC as the dependent variable and the 7 decision-making parameters as independent variables. In only this model, median round 2 scores for each scenario were dichotomized into appropriate (scores 7 to 9) versus not appropriate (scores 1 to 6) for stent omission.

To provide context to the results, we identified all URS cases in the MUSIC registry between 2016 and 2019 that met criteria for uncomplicated URS (supplementary fig. 6, <https://www.urologypracticejournal.com>). These were assigned a corresponding AC score and the proportion with stent placement were determined. The association between AC scores and stenting rates was calculated with Spearman’s correlation coefficient. Only practices with greater than or

equal to 10 uncomplicated URS procedures appropriate or inappropriate for stent omission in the MUSIC registry were included. Scenarios with disagreement were excluded from the registry analysis. Statistical analysis was completed using SAS® 9.4 (SAS, Cary, North Carolina).

**Results**

Of the 144 clinical scenarios, 38 (26%) were scored highly inappropriate, 50 (36%) inappropriate, 30 (21%) uncertain, 20 (14%) appropriate and 6 (4%) as highly appropriate for ureteral stent omission. Figure 3 displays a heatmap of median appropriateness scores by each scenario. Most of the scenarios appropriate for stent omission can be found at the top of the heatmap, within the pre-stented scenarios. Of the 26 scenarios appropriate for stent omission, 21 (81%) were pre-stented. If a UAS was employed, only pre-stented



**Figure 4.** Forest plot of odds ratios of panelist scoring clinical scenario appropriate for stent omission by variable. UA, urinalysis.

scenarios were appropriate for stent omission. There were no scenarios with ureteral dilation performed that were appropriate for stent omission. Additionally, no scenarios with stones greater than 10 mm and without pre-stenting were appropriate for stent omission.

Each of the chosen variables significantly impacted stent omission decision making (fig. 4). The parameter with the greatest association was the absence of ureteral dilation (OR 14.6; 95% CI 8.08–26.49). Conversely, stone location had the least impact on decision making, evidenced by ureteral (vs renal) stones having the lowest odds of being scored appropriate for omission (OR 1.5; 95% CI 1.16–2.05).

We observed a wide distribution of agreement among panelists for individual scenarios (fig. 5). A total of 11 scenarios met RAM criteria for disagreement and are shaded in figure 5. In general, the least agreement (greatest standard deviation) was seen in scenarios with pre-stenting and a treated positive urine culture. The greatest agreement was seen in scenarios highly inappropriate for stent omission such as those without pre-stenting, stones greater than 10 mm, a treated positive urine culture and ureteral dilation performed.


We identified 5,181 cases that met AC for uncomplicated URS. A stent was placed in 3,654 (70.5%). AC scores correlated with stenting rates in these cases ( $r_s = -0.967$ ; fig. 6, A). Figure 6 also displays the variation in stenting rates between practices among cases appropriate (fig. 6, B) and inappropriate (fig. 6, C) for stent omission. Of the 2,735 cases appropriate for stent omission, a stent was placed in 1,659 (60.6%), and practice-level rates varied from 25.0% to 98.3%. Of the 1,881 cases inappropriate for omission, a stent was placed in 1,608 (85.5%), and practice-level rates varied from 35.7% to 100%.

## Discussion

We sought to develop AC for stent omission following uncomplicated URS by using the RAM. Our study has several key findings. First, we created a consensus definition of uncomplicated URS to identify patients suitable for consideration of stent omission. Second, we identified 7 objective variables that affect decision making for stent omission. Third, we created AC for stent omission following URS. Lastly, we found that stenting rates correlated with our AC. However, there was variation in practice patterns and a high rate of stenting, even among cases highly appropriate for stent omission. Collectively, these findings demonstrate that appropriate use of stent omission after uncomplicated URS is currently underutilized.

Few studies have investigated decision making about stent placement or omission following URS. A recent Cochrane review assessing outcomes associated with stent placement following URS acknowledged the need for higher quality evidence.<sup>20</sup> AUA guidelines state clinicians may omit ureteral stenting if all the following criteria are met: normal contralateral kidney, normal renal function, no impediments to stone fragment clearance, no ureteric injury and no planned secondary URS.<sup>1</sup> EAU guidelines similarly advocate that routine stenting after uncomplicated URS is unnecessary; however, no criteria are provided.<sup>2</sup> In our study, the RAM panel created a consensus definition of uncomplicated URS based on clinical experience. Given the subjective nature of the topic, some considerations remain unclear. Although nonballoon ureteral dilation was chosen as a variable, none of the scenarios with dilation performed met AC for omission and its absence was the strongest predictor being scored






**Figure 5.** Heatmap of standard deviation of round 2 scores among panelists for all clinical scenarios. Darker blue represents less agreement (higher standard deviation). Shaded squares meet RAM manual criteria for disagreement. *UAS+*, UAS used. *UAS-*, no UAS used. *Frag+*, yes, fragments left behind. *Frag-*, no fragments left behind.

appropriate for omission. There is limited evidence regarding the safety of stent omission following ureteral dilation.<sup>21,22</sup> Future research should investigate the type and size of ureteral dilators used in order to provide additional clarity.

The majority of scenarios appropriate for stent omission occurred in pre-stented patients; however, many pre-stented scenarios were either inappropriate or uncertain. While some may advocate for stent omission in all pre-stented uncomplicated



**Figure 6.** A, ureteral stent placement rates following uncomplicated URS in the MUSIC registry by assigned stent omission AC score. Number of stented cases for each score and Spearman’s correlation coefficient (*rs*) are displayed. B, rates of ureteral stent placement among MUSIC practices for cases determined to be appropriate. C, rates of ureteral stent placement among MUSIC practices for cases determined to be inappropriate. Data shown for practices with 10 or more cases in each category.

URS,<sup>23</sup> this sentiment was not shared by the panel. Additionally, previous studies have demonstrated the safety of stent omission following UAS use in select pre-stented patients.<sup>24,25</sup> Our panel found that stent omission was appropriate in pre-stented scenarios with UAS use if the stone was less than or equal to 10 mm, across a variety of other parameters.

Surprisingly, stone location had little effect on stent omission decision making. The safety of stent omission following uncomplicated URS for ureteral stones is well established.<sup>3,22,25–27</sup> However, no randomized trial has assessed the safety of stent omission for patients with renal stones.<sup>20,22,28,29</sup> Despite having the least impact on decision making of our chosen variables, we found that scenarios with ureteral stones were significantly more likely to be appropriate for stent omission than scenarios with renal stones. Lastly, we found that stone size was associated with decision making, and contrary to AUA guidelines,<sup>1</sup> stones >10 mm were considered inappropriate for stent omission if not pre-stented.

Our study has several limitations. Our criteria for uncomplicated URS should be validated in future research. It was not possible to capture every variable under consideration during stent omission decision making. Several factors cannot be objectively quantified and were not included as variables. The panel spent considerable time discussing “tightness” of the ureter while passing the ureteroscope, degree of stone impaction, operative technique (dusting versus fragmentation/extraction) and size criteria for fragments; however, it was ultimately decided that variables such as these were too subjective for inclusion. The amount of time needed to score scenarios is a constraint of the RAM, and it was not feasible to include every proposed variable. Specifically, the panel discussed including preoperative hydronephrosis and stratification of the ureteral location but concluded these were not of sufficient importance. In the retrospective analysis, the MUSIC registry does not capture every factor included in the uncomplicated URS definition such as operative time, neurogenic bladder or incomplete bladder emptying. Practice patterns in Michigan may not be representative of international trends, where stenting rates may be much higher.<sup>3</sup> Lastly, the term “inappropriate” in the RAM is not meant to provide judgment from a patient safety or medicolegal perspective, but rather expert opinion in the absence of strong scientific evidence.<sup>11</sup> In future publications, it is possible to combine the 9 categories into 3 broad categories of stent omission such as “consider,” “indeterminate” and “not consider,” which may be easier for clinicians to implement.

Limitations notwithstanding, the implications of our work are substantial and we have laid the foundation for future efforts to address variation in stenting practices. In the section on future research in the AUA surgical management

of stone guidelines, it is recommended that future efforts should better identify patients safe for stent omission.<sup>1</sup> Our study is the first instance of a standardized data-driven method being used to understand stenting after URS. As a result of this project, we have created a clinical decision aid for dissemination to all practices in Michigan (supplementary fig. 7, <https://www.urologypracticejournal.com>). All resources are freely available at [www.musicurology.com/rocks](http://www.musicurology.com/rocks). We also aim to develop target rates of stent omission for different scenarios, which can be tracked as a quality measure in the future. However, we expect widespread adoption will take time and, thus, a prospective analysis of our results did not occur in the current study.

Future research should focus on validation of the safety of stent omission in the aforementioned appropriate scenarios, as this should address the heterogeneity among panelists. The AC developed provide a framework for clinical trials, especially in scenarios found to be uncertain, such as the setting of an appropriately treated positive urine culture or non-pre-stented patients. Importantly, investigation into the linkage between patient-reported outcomes and stenting practices has not been previously done but we have begun to capture this. Finally, if appropriate stent omission reduces health care utilization and improves health-related quality of life, an increase in payment by payers for procedural services that includes stent omission may be an important lever for reducing utilization and changing physician behavior, thereby minimizing variation.<sup>30</sup>

## Conclusions

We identified 7 objective variables that impact decision making for stent placement after uncomplicated URS. Through the development of AC, we defined scenarios that were appropriate and inappropriate for stent omission. Data from the MUSIC registry confirmed decreasing stenting rates with increasing AC for stent omission scores. However, there was significant practice variation. Implementation of these AC into practice could help address variation, reduce stenting rates and improve the quality of care.

## Acknowledgments

The authors acknowledge the significant contributions of the clinical champions, urologists, administrators and data abstractors in each participating MUSIC practice (details can be found at [www.musicurology.com](http://www.musicurology.com)), as well as members of the MUSIC Coordinating Center at the University of Michigan. We thank our patient advocates for their support, in particular Dennis Sitek, who provided valuable insight to our panelists. Lastly, we thank Michael Cher, MD, who forged the way

with the Appropriateness Criteria for Active Surveillance of Prostate Cancer panel, for his guidance and expertise through this process.

## References

- Assimos D, Krambeck A, Miller NL et al: Surgical management of stones: American Urological Association/Endourological Society guideline, PART I. *J Urol* 2016; **196**: 1153.
- Türk C, Petřík A, Sarica K et al: EAU guidelines on interventional treatment for urolithiasis. *Eur Urol* 2016; **69**: 475.
- Musulmanoglu AY, Fuglsig S, Frattini A et al: Risks and benefits of postoperative double-J stent placement after ureteroscopy: results from the clinical research office of Endourological Society ureteroscopy global study. *J Endourol* 2017; **31**: 446.
- Hiller SC, Daignault-Newton S, Pimentel H et al: Ureteral stent placement following ureteroscopy increases emergency department visits in a statewide surgical collaborative. *J Urol* 2021; **205**: 1710.
- Joshi HB, Okeke A, Newns N et al: Characterization of urinary symptoms in patients with ureteral stents. *Urology* 2002; **59**: 511.
- Pengfei S, Yutao L, Jie Y et al: The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: a systematic review and meta-analysis. *J Urol* 2011; **186**: 1904.
- Shao Y, Zhuo J, Sun XW et al: Nonstented versus routine stented ureteroscopic holmium laser lithotripsy: a prospective randomized trial. *Urol Res* 2008; **36**: 259.
- San Juan J, Hou H, Ghani KR et al: Variation in spending around surgical episodes of urinary stone disease: findings from Michigan. *J Urol* 2018; **199**: 1277.
- Staubli SE, Mordasini L, Engeler DS et al: Economic aspects of morbidity caused by ureteral stents. *Urol Int* 2016; **97**: 91.
- Birkmeyer JD, Reames BN, McCulloch P et al: Understanding of regional variation in the use of surgery. *Lancet* 2013; **382**: 1121.
- Fitch K, Bernstein SJ, Aguilar MD et al.: The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, California: RAND Corporation 2001.
- Lawson EH, Gibbons MM, Ingraham AM et al: Appropriateness criteria to assess variations in surgical procedure use in the United States. *Arch Surg* 2011; **146**: 1433.
- Desai NR, Bradley SM, Parzynski CS et al: Appropriate use criteria for coronary revascularization and trends in utilization, patient selection, and appropriateness of percutaneous coronary intervention. *JAMA* 2015; **314**: 2045.
- Cher ML, Dhir A, Auffenberg GB et al: Appropriateness criteria for active surveillance of prostate cancer. *J Urol* 2017; **197**: 67.
- Singhal U, Tosoian JJ, Qi J et al: Overtreatment and underutilization of watchful waiting in men with limited life expectancy: an analysis of the Michigan Urological Surgery Improvement Collaborative registry. *Urology* 2020; **145**: 190.
- Auffenberg GB, Lane BR, Linsell S et al: A roadmap for improving the management of favorable risk prostate cancer. *J Urol* 2017; **198**: 1220.
- Dauw CA, Ghani KR, Qi J et al: Variable use of postoperative imaging following ureteroscopy: results from a statewide quality improvement collaborative. *Urology* 2020; **136**: 63.
- Hiller SC, Qi J, Leavitt D et al: Ureteroscopy in patients taking anticoagulant or antiplatelet therapy: practice patterns and outcomes in a surgical collaborative. *J Urol* 2021; **205**: 833.
- National Institute for Health and Care Excellence: NICE Guideline—renal and ureteric stones: assessment and management: NICE (2019) renal and ureteric stones: assessment and management. *BJU Int* 2019; **123**: 220.
- Ordóñez M, Hwang EC, Borofsky M et al: Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi. *Cochrane Database Syst Rev* 2019; **2**: CD012703.
- Bağeskioğlu B, Sofikerim M, Demirtaş A et al: Is ureteral stenting really necessary after ureteroscopic lithotripsy with balloon dilatation of ureteral orifice? A multi-institutional randomized controlled study. *World J Urol* 2011; **29**: 731.
- Borboroglu PG, Amling CL, Schenkman NS et al: Ureteral stenting after ureteroscopy for distal ureteral calculi: a multi-institutional prospective randomized controlled study assessing pain, outcomes and complications. *J Urol* 2001; **166**: 1651.
- Bower PE, Pereira J, Al-Alao O et al: Indications for stent omission after ureteroscopic lithotripsy defined: a single-institution experience with cost analysis. *Arab J Urol* 2019; **17**: 206.
- Astroza G, Catalán M, Consigliere L et al: Is a ureteral stent required after use of ureteral access sheath in presented patients who undergo flexible ureteroscopy? *Cent Eur J Urol* 2017; **70**: 88.
- Torricelli FC, De S, Hinck B et al: Flexible ureteroscopy with a ureteral access sheath: when to stent? *Urology* 2014; **83**: 278.
- Denstedt JD, Wollin TA, Sofer M et al: A prospective randomized controlled trial comparing nonstented versus stented ureteroscopic lithotripsy. *J Urol* 2001; **165**: 1419.
- Ibrahim HM, Al-Kandari AM, Shaaban HS et al: Role of ureteral stenting after uncomplicated ureteroscopy for distal ureteral stones: a randomized, controlled trial. *J Urol* 2008; **180**: 961.
- Srivastava A, Gupta R, Kumar A et al: Routine stenting after ureteroscopy for distal ureteral calculi is unnecessary: results of a randomized controlled trial. *J Endourol* 2003; **17**: 871.
- Isen K, Bogatekin S, Em S et al: Is routine ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy for lower ureteral stones larger than 1 cm? *Urol Res* 2008; **36**: 115.
- Shah PK, Linsell S, Qi J et al: Limiting opioid overprescription after prostatectomy: how payer-provider collaboration can lead to improved patient safety and reimbursement. *NEJM Catal Innov Care Deliv* 2020; <https://doi.org/10.1056/CAT.20.0140>.

## Editorial Commentaries

Placing ureter stents after ureteroscopy (URS) is the generally accepted standard of care to maximize patient safety, just as treating prostate cancer was felt to be the generally accepted standard of care for all patients diagnosed. That being said, we have come to learn that prostate cancer is heterogeneous and based upon certain risk factors that active surveillance may be the preferred choice for certain patients. Similarly, URS is also heterogeneous, and despite studies from even decades ago showing the safety of stent omission after URS in appropriately selected patients, the adoption of such a practice has been slow. Why? If we compare the situation to that of active surveillance for prostate cancer, significant barriers needed to be addressed before widespread adoption, including having enough published literature proving the safety along with having published appropriateness guidelines. Were we to have similar appropriateness guidelines available for stent omission after URS in the appropriately selected patient, we may see a more widespread

adoption. Studies like this serve as a springboard for further discussion to improve the care we take of our patients, which may end up improving patient outcomes. However, we do need to remember that we have yet to prove an improvement in health-related quality of life and a reduction in health care costs with selective stent omission, the data for which would be helpful in our efforts to ensure we are providing the best and most appropriate care possible.

**Jonathan Rubenstein<sup>1</sup>**

<sup>1</sup>*Chair*

*Coding and Reimbursement Committee*

*American Urological Association*

*Compliance Officer*

*Medical Director of Coding and Reimbursement*

*United Urology Group and Chesapeake Urology*

*Associates*

*Towson, Maryland*

AUA Guidelines are a major step forward in urological care, and their phrasing can make a significant difference. For example, the stone guidelines recommend against routine stents after shockwave lithotripsy or prior to ureteroscopy, but imply stenting should be the default by stating clinicians “may omit” stenting in specified circumstances after ureteroscopy.

These authors add to the dialogue, but there is room to push the question further in future studies.

Let’s be honest—many patients are more miserable from a stent than from sequelae of the procedure. As such, future guidelines panels should consider whether justification for omitting stenting is the question, or do we have clear justification for stenting?

**J. Stephen Jones**

*Editor*